LOS ANGELES --(BUSINESS WIRE)--Aug. 21, 2026-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of
Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC LOS ANGELES --(BUSINESS WIRE)--Jul. 22, 2026-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug
LOS ANGELES --(BUSINESS WIRE)--Jun. 4, 2026-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu,
Company selected for the Leaders in Drug Resistance Development award LOS ANGELES --(BUSINESS WIRE)--May 14, 2026-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026
LOS ANGELES --(BUSINESS WIRE)--May 8, 2026-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday, June 29, 2026.
Company selected as an Emerald honoree for Innovator of Biotech Solutions LOS ANGELES --(BUSINESS WIRE)--Apr. 15, 2026-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the
The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Opportunity LOS ANGELES --(BUSINESS WIRE)--Mar. 2, 2026-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage
Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar lung cancer market. LOS ANGELES --(BUSINESS WIRE)--Feb. 26, 2026-- Kairos Pharma, Ltd.
CSO Neil Bhowmick to deliver company presentation and will be available for investor meetings LOS ANGELES --(BUSINESS WIRE)--Jan. 20, 2026-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will
